Anti-inflammatory effects of rosuvastatin treatment in coronary artery ectasia patients in different age groups

Chenghui Fan, Ying Hao, Yonghua Liu, Xiaolin Li, Zhenhao Huang, Yu Luo, Ruilin LiResearch Square 2020 · DOI

Abstract

Coronary artery ectasia (CAE) is characterized by abnormal coronary artery dilation, often linked to systemic inflammation. This study investigated the relationship between CAE and inflammatory markers—high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6)—and hypothesized that patient age significantly influences the efficacy of anti-inflammatory therapy. Analyzing 217 CAE patients across three age groups, researchers found that younger patients (≤50 years) exhibited higher baseline inflammation but also experienced the most significant reductions in inflammatory markers following six months of rosuvastatin treatment. These findings suggest that early intervention with statin therapy is particularly effective in younger populations.

Introduction

Coronary artery ectasia (CAE) involves a localized or diffuse dilation of the coronary arteries to at least 1.5 times the diameter of adjacent normal segments. While its pathophysiology is often associated with atherosclerosis, the precise mechanisms remain elusive. Emerging evidence highlights inflammation as a primary driver of the condition. Specifically, markers like Hs-CRP and IL-6 are elevated in CAE patients, yet clinical guidelines for managing this inflammation are not yet standardized. This study aimed to determine if rosuvastatin, a common HMG-CoA reductase inhibitor with known pleiotropic anti-inflammatory effects, works differently across various age demographics.

Methods and Cohort Selection

The study involved a prospective analysis of patients treated at three major medical centers in China between 2015 and 2019. From an initial screening of 6,542 patients undergoing coronary angiography, 302 were diagnosed with CAE, representing a 4.6% prevalence. After applying exclusion criteria (such as heart failure or renal dysfunction), 217 CAE patients were enrolled and compared against 73 normal controls (NC).

Figure 1: Study flow diagram illustrating the screening of 6,542 patients and the final allocation into CAE age groups and the control group.

Participants were categorized into three age-based cohorts:

  • CAE-A: Age ≤50 years (n=60)
  • CAE-B: Age 50–70 years (n=83)
  • CAE-C: Age >70 years (n=74)

All CAE patients received a daily dose of 10 mg rosuvastatin. Serum levels of Hs-CRP and IL-6 were measured at baseline and at a 6-month follow-up to assess treatment impact.

Key Insights: The Inflammation Signature

Statistical analysis confirmed that inflammatory markers are not merely associated with CAE but are independent predictors of the disease. Logistic regression identified Hs-CRP (OR=1.782, 95% CI: 1.124-2.014) and IL-6 (OR=1.584, 95% CI: 1.112-1.986) as significant indicators.

A notable finding was the "Youth Paradox": the youngest group (CAE-A) presented with the highest baseline levels of inflammation (Hs-CRP: 32.3 mg/L) compared to the oldest group (CAE-C: 22.5 mg/L). This suggests that in younger patients, CAE may be driven by a more acute or "primed" immune response, whereas older patients may experience more chronic, low-grade inflammation.

Age-Dependent Treatment Efficacy

While rosuvastatin successfully reduced inflammatory markers across all age groups, the magnitude of the reduction was significantly higher in younger patients. This indicates that the inflammatory component of CAE in younger individuals is more responsive to pharmacological intervention.

Figure 2: Comparison of Hs-CRP and IL-6 levels before and after 6 months of rosuvastatin therapy, showing the greatest reduction in the youngest cohort (CAE-A).

As shown in the data, the reduction in Hs-CRP for the youngest group was approximately 15.1 mg/L (~47% decrease), while the oldest group saw a reduction of only 4.5 mg/L (~20% decrease). Similar trends were observed for IL-6, where the youngest cohort saw a reduction nearly three times greater than that of the oldest cohort (5.9 pg/dL vs. 1.9 pg/dL).

Conclusion

The study concludes that rosuvastatin is an effective anti-inflammatory agent for CAE patients, but its benefits are age-dependent. The heightened responsiveness in younger patients suggests a critical window for early intervention. In older patients, the persistence of inflammation despite therapy may indicate that arterial wall damage becomes less reversible over time. These results underscore the importance of early diagnosis and the prompt initiation of statin therapy to mitigate inflammatory progression in coronary artery ectasia.

Summary updated

Abstract

<title>Abstract</title> <bold>Background: </bold>Coronary artery ectasia (CAE) is an angiographic finding of abnormal coronary dilatation. The role of inflammation in atherosclerosis is becoming increasingly well known. This study investigated the relationship between CAE and serum levels of high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6) to test our hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy for CAE.<bold> </bold><bold>Methods: </bold>We conducted a prospective analysis of 217 patients with CAE treated at the Department of Cardiology, Shanghai East Hospital, Shanghai East Hospital (Ji'an Campus), and Cardiovascular Medicine of Baoshan People’s Hospital of Yunnan Province, from January 1, 2015 to July 30, 2019. Baseline data of patients, including sex, age, hypertension, hyperlipidemia, and diabetes, were collected from patient medical records. Study participants were grouped by age as follows: CAE-A (age ≤50 years), CAE-B (50 years &lt;age ≤70 years), and CAE-C (age &gt;70). Additionally, there was a normal control (NC) group with normal coronary arteries.<bold>Results:</bold> All patients received oral rosuvastatin therapy (10 mg, QN quaque nocte) when they were diagnosed with CAE and maintained good follow-up, with a loss rate of 0.0% at the 6-month follow-up. The NC group (n = 73, with normal coronary arteries) received regular symptom-relieving treatments and rosuvastatin therapy. Among these four groups, the inflammatory markers were significantly higher in patients with CAE than in the NCs (p&lt;0.01). Logistic regression analysis showed that Hs-CRP (OR=1.782, 95% CI: 1.124-2.014, P=0.021) and IL-6 (OR=1.584, 95% CI: 1.112-1.986, P=0.030) were independent predictors of CAE. The inflammatory markers in the CAE-A group were higher than those in the CAE-B group, which were higher than those in the CAE-C group. Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in Hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which, again, were higher than those in the CAE-C group. <bold>Conclusions:</bold> Anti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy in CAE patients.
BibTeX
@inproceedings{fan2020anti,
  author = {Chenghui Fan and Ying Hao and Yonghua Liu and Xiaolin Li and Zhenhao Huang and Yu Luo and Ruilin Li},
  title = {{Anti-inflammatory effects of rosuvastatin treatment in coronary artery ectasia patients in different age groups}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.3.rs-21391/v2},
}
Figure